.jpg)
Igal Louria-Hayon
Rambam Health Care Campus, IsraelPresentation Title:
Lnk Adaptor Protein: A Novel Target to Improve Cell Therapy in Solid Tumors
Abstract
Adoptive cell therapy with chimeric antigen receptor (CAR) T cells aims to redirect the patient's immune system to specifically target and eliminate cancer cells. CAR T cells are engineered with antigen recognition components fused to signaling and costimulatory domains, which have shown significant success in treating B cell malignancies. However, the response rates in patients with solid tumors are less favorable. The primary challenges in CAR T cell therapy for solid cancers include enhancing CAR T cell trafficking to the tumor site and their expansion within the tumor microenvironment. Lnk, an adaptor protein extensively expressed in the hematopoietic system, binds to phosphorylated tyrosine residues on intracellular protein targets via its SH2 domain, inhibiting downstream signaling of cytokine receptor pathways. Our research demonstrated that tumors in Lnk-deficient (Lnk-/-) mice were one-third the size of those in wild-type (WT) mice, and Lnk-/- tumors had a higher population of tumor-infiltrating cytotoxic CD8+ T cells (CTLs) compared to WT mice. Both in vivo and in vitro chemotaxis experiments showed that Lnk-/- CTLs have enhanced migration towards IL8. These results highlight Lnk as a novel regulator of CTL migration and infiltration into solid tumors, proposing Lnk as a promising new target for improving the efficacy of immunotherapy by enhancing T cell infiltration and anti-tumor activity.
Biography
Louria-Hayon holds a Ph.D. in Tumor Immunology from the Hebrew University and conducted postdoctoral research in the field of cancer signaling and cell communication at Mount Sinai Hospital in Toronto, Canada. Currently, He serves as the Head of the lab for leukemia and cancer signaling at the Clinical Research Institute at Rambam. He is also the director of the Medical Cannabis Research Center at Rambam and serves as the director of SPARK Haifa.
Organization Location
1309 Coffeen Avenue, STE 1200, Sheridan, Wyoming 82801 USA
Mail us at
Program Enquiry
oncology@scientexconferences.com
General Enquiry
contact@scientexconferences.com
Registration Enquiry
finance@scientexconferences.com
oncology@scientexconferences.com
Our Social Presence
Call us at
USA :(+1) 323 677 0554